UNC13A targeting small molecule therapeutic - Maze Therapeutics
Latest Information Update: 09 Mar 2023
At a glance
- Originator Maze Therapeutics
- Class Small molecules
- Mechanism of Action Nerve tissue protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jan 2023 UNC13A targeting small molecule therapeutic - Maze Therapeutics is available for licensing as of 16 Jan 2023. https://mazetx.com/pipeline/ (Maze Therapeutics pipeline, January 2023)
- 16 Jan 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) (Maze Therapeutics pipeline, January 2023)